This is a news story, published by NBC News, that relates primarily to Pfizer news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from NBC News, you can click here:
more news from NBC NewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
colorectal cancer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest cancer mutation news, standard chemotherapy treatments news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
standard chemotherapy drugNBC News
•Health
Health
85% Informative
A combination drug treatment doubled survival time for patients with an aggressive form of colorectal cancer.
The three -treatment combination included a standard chemotherapy drug, an antibody drug called cetuximab and a pill from Pfizer called Braftovi .
The Food and Drug Administration granted the treatment fast-track approval as a first -line approach in December .
VR Score
90
Informative language
93
Neutral language
16
Article tone
semi-formal
Language
English
Language complexity
58
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
5
Source diversity
5
Affiliate links
no affiliate links
